Top Markets
#1 Seeker Seeker +45.46%
#2 Helium Helium +36.27%
#3 TENDIES TENDIES +29.33%
#4 Pons Pons +28.89%
#5 pipedog pipedog +20.31%
#6 UnifAI Network UnifAI Network +19.15%
#7 Zylo Ecosystem Zylo Ecosystem +19.08%
#8 Bounce Bounce +18.99%
#9 ZKsync ZKsync +14.63%
#10 Zora Zora +14.14%
Coin of the day
Seeker Seeker
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang in Aktien #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Aktienkurs
$9.50
Zuletzt synchronisiert: 2025-01-08
Marktkapitalisierung
$819.52M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Poseida Therapeutics, Inc. (PSTX)

Kategorie

Healthcare
P/S-Verhältnis für Poseida Therapeutics, Inc. (PSTX)
P/S-Verhältnis zum August 2026 TTM: 14.31
Laut den neuesten Finanzberichten und dem Aktienkurs von Poseida Therapeutics, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 14.31. Am Ende des Jahres 2022 lag das P/S-Verhältnis bei 2.92.
P/S-Verlauf für Poseida Therapeutics, Inc. von 2016 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 14.31 205.78%
2023 4.68 60.18%
2022 2.92 -99.98%
2021 13.55K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 204.33 119.21%
2016 93.21 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -28.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -29.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -79.37%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -21.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH